Multiple Sclerosis Therapeutics
eBook - PDF

Multiple Sclerosis Therapeutics

  1. 928 pages
  2. English
  3. PDF
  4. Available on iOS & Android
eBook - PDF

Multiple Sclerosis Therapeutics

About this book

Since the publication of the previous edition of this volume, there has been substantial progress in a number of areas of multiple sclerosis (MS) research. Although immunosuppressive treatments continue to be developed and refined, more targeted immunomodulatory therapies are surfacing as we learn more about how the immune system works in health an

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Multiple Sclerosis Therapeutics by Eli Minkoff,Eli Baker, Jeffrey A. Cohen,Richard A. Rudick, Jeffrey A. Cohen, Richard A. Rudick in PDF and/or ePUB format, as well as other popular books in Medicine & Neurology. We have over one million books available in our catalogue for you to explore.

Information

Publisher
CRC Press
Year
2007
Print ISBN
9781841845258
eBook ISBN
9780203012055
Edition
3
Topic
Medicine
Subtopic
Neurology

Table of contents

  1. Front cover
  2. Table of contents
  3. Contributors
  4. Preface to second edition
  5. Preface to third edition
  6. SECTION I: Introduction
  7. CHAPTER 1. Aspects of multiple sclerosis that relate to trial design and clinical management
  8. CHAPTER 2. Biological concepts of multiple sclerosis pathogenesis and relationship to treatment
  9. CHAPTER 3. The multiple sclerosis disease process as characterized by magntic resonance imaging
  10. SECTION II: Clinical trial methodology
  11. CHAPTER 4. Measures of neurological impairment and disability in multiple sclerosis
  12. CHAPTER 5. Assessment of neuropsychological function in multiple sclerosis
  13. CHAPTER 6. Health-related quality of life assessment in multiple sclerosis
  14. CHAPTER 7. Measures of gadolinium enhancement, T1 black holes and T2-hyperintense lesions on magnetic resoncance imaging
  15. CHAPTER 8. Measures of magnetization transfer in multiple sclerosis
  16. CHAPTER 9. Measuremnt of central nervous system atrophy in multiple sclerosis
  17. CHAPTER 10. Axonal pathology in patients with multiple sclerosis: evidence from in vivo proton magnetic resonance spectroscopy
  18. CHAPTER 11. Functional imaging in multiple sclerosis
  19. CHAPTER 12. Magnetc resonance imaging of pathway-specific structure and function in multiple sclerosis
  20. CHAPTER 13. Optical coherence tomography to monitor neuronal integrity in multiple sclerosis
  21. CHAPTER 14. Biomarkers in multiple sclerosis
  22. CHAPTER 15. The process of drug development and approval in the Untied States, the European Union and Canda
  23. CHAPTER 16. Selection and interpretation of end-points in multiple sclerosis clinical trials
  24. CHAPTER 17. Clinical trial logistics
  25. CHAPTER 18. The challenge of long-term studies in multiple sclerosis: use of pooled data, historical controls and observation studies to determine efficacy
  26. CHAPTER 19. Alternative designs for multiple sclerosis clinical trials
  27. CHAPTER 20. Ethical considerations in multiple sclerosis clinical trials
  28. CHAPTER 21. Pharmacognetics and pharmacognomics in multiple sclerosis
  29. SECTION III: Clinical trials of multiple sclerosis therapies
  30. CHAPTER 22. Interferons in relapsing-remitting multiple sclerosis
  31. CHAPTER 23. Interferons in secondary progressive multiple sclerosis
  32. CHAPTER 24. Neurtralizing antibodies directed against interferon
  33. CHAPTER 25. Glatiramer acetate as therapy for multiple sclerosis
  34. CHAPTER 26. Use of mitoxantrone to treat multiple sclerosis
  35. CHAPTER 27. Use of cyclophosphamide and other immunosuppressants to treat multiple sclerosis
  36. CHAPTER 28. Natalizumab in multiple sclerosis
  37. CHAPTER 29. High-dose methylprednisolone in the treatment of multiple sclerosis
  38. CHAPTER 30. Intravenous immunoglobulin in multiple sclerosis
  39. CHAPTER 31. Therapeutic plasma exchange for multiple sclerosis
  40. CHAPTER 32. Statins in multiple sclerosis
  41. CHAPTER 33. Stem cell transplantation for multiple sclerosis
  42. CHAPTER 34. T cell-based therapies in multiple sclerosis
  43. CHAPTER 35. B cell-based therapies for multiple sclerosis and related diseases
  44. CHAPTER 36. Chemokines and central nervous system inflammation: relevance to multiple sclerosis
  45. CHAPTER 37. Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis
  46. CHAPTER 38. Neuroprotein in multiple sclerosis
  47. CHAPTER 39. Combination therapy in multiple sclerosis
  48. CHAPTER 40. Fampridine in multiple sclerosis
  49. CHAPTER 41. Complementary and alternative treatments in multiple sclerosis
  50. SECTION IV: Therapy in clinical practice
  51. CHAPTER 42. Disease-modifying therapy for multiple sclerosis in clinical practice
  52. CHAPTER 43. Treatement for patients with primary progressive multiple sclerosis
  53. CHAPTER 44. Use of magnetic resonance imaging in clinical management of multiple sclerosis
  54. CHAPTER 45. Fatigue in multiple sclerosis
  55. CHAPTER 46. Management of spasticity in multiple sclerosis
  56. CHAPTER 47. Management of bladder and sexual dysfunction in multiple sclerosis
  57. CHAPTER 48. Depression in multiple sclerosis
  58. CHAPTER 49. Treatment of pain, paresthesias and paroxyslam disorders in multiple sclerosis
  59. CHAPTER 50. Rehabilitation in multiple sclerosis patients
  60. Index
  61. Back cover